特应性皮炎患者的恶性肿瘤风险:基于人群的队列研究
该研究利用英国健康改善网络1994-2015年电子健康记录,匹配儿童和成人特应性皮炎(AD)患者与无AD患者,分析恶性肿瘤风险。总体恶性肿瘤风险在AD与无AD间无显著差异(儿童HR 1.02,成人HR 1.00);但重度AD与淋巴瘤风险升高相关(儿童HR 3.18,成人风险约2倍),轻度AD与儿童非黑色素瘤皮肤癌风险升高相关(HR 1.55)。
要点
- 总体恶性肿瘤风险在AD与无AD患者间无显著差异。
- 重度AD与淋巴瘤风险升高相关,儿童HR 3.18(排除CTCL),成人风险约2倍。
- 轻度AD儿童非黑色素瘤皮肤癌风险升高(HR 1.55)。
核心结论
- 流行病学证据不支持AD整体存在较强的恶性肿瘤风险,但重度AD可能增加淋巴瘤风险。
研究设计与样本
- 基于英国健康改善网络1994-2015年电子健康记录的队列研究,儿童(<18岁)和成人(≥18岁)AD患者按年龄、诊所和索引日期与无AD患者匹配。
主要发现
- 儿童AD与无AD的总体恶性肿瘤调整风险无差异(HR 1.02,95%CI 0.92-1.12)。
- 儿童重度AD与淋巴瘤风险升高相关(HR 3.18,95%CI 1.41-7.16,排除CTCL),轻度AD与非黑色素瘤皮肤癌风险升高相关(HR 1.55,95%CI 1.06-2.27)。
- 成人AD与无AD的总体恶性肿瘤调整风险无差异(HR 1.00,95%CI 0.99-1.02);重度AD非CTCL淋巴瘤风险约2倍。
- 成人AD皮肤癌风险略高(HR 1.06,95%CI 1.04-1.08),实体癌风险略低(HR 0.97,95%CI 0.96-0.98),结果因具体癌症和AD严重度而异。
关键数值与推荐
- 儿童AD恶性肿瘤发病率1.9-3.4/10 000人年,无AD为2.0/10 000人年;成人AD为97.4-125.3/10 000人年,无AD为103.7/10 000人年。
临床怎么用
- 临床实践中应关注重度AD患者的淋巴瘤风险,尤其是儿童重度AD患者。
- 对于轻度AD儿童,需注意非黑色素瘤皮肤癌风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is associated with immunological dysfunction, which may influence cancer development. Previous studies of AD and cancer demonstrate inconsistent results and few of these studies examined children or AD severity and treatment. OBJECTIVES: To determine malignancy risk among children and adults with AD. METHODS: We conducted a cohort study using electronic health records data from UK general practices in The Health Improvement Network between 1994 and 2015. Children (< 18 years old) and adults (≥ 18 years old) with AD were matched on age, practice and index date to patients without AD. AD was categorized as mild, moderate or severe using treatments and dermatology referrals as proxies. The primary outcome was any incident malignancy, including in situ malignancy, identified using diagnosis codes and categorized into haematological, skin and solid organ malignancies. Secondary outcomes included specific malignancies: leukaemia, lymphoma, melanoma, nonmelanoma skin cancer (NMSC) and common solid-organ cancers. RESULTS: Among 409 431 children with AD (93.2% mild, 5.5% moderate, 1.3% severe) and 1 809 029 children without AD who had median follow-up of 5-7 years, the incidence rates of malignancy were 1.9-3.4 and 2.0 per 10 000 person-years (PY), respectively. The adjusted risk of malignancy overall did not differ with respect to AD [hazard ratio (HR) 1.02 (95% confidence interval 0.92-1.12)]. Severe AD was associated with increased lymphoma risk [HR 3.18 (1.41-7.16), excluding cutaneous T-cell lymphoma (CTCL)], and mild AD was associated with increased NMSC risk [1.55 (1.06-2.27)]. Among 625 083 adults with AD (65.7% mild, 31.4% moderate, 2.9% severe) and 2 678 888 adults without AD who had median follow-up of 5 years, incidence rates of malignancy were 97.4-125.3 per 10 000 PY and 103.7 per 10 000 PY, respectively. The adjusted risk of any malignancy did not differ with respect to AD [HR 1.00 (0.99-1.02)]. However, adults with severe AD had a twofold higher risk of non-CTCL lymphoma. AD was also associated with slightly higher skin cancer risk [HR 1.06 (1.04-1.08)] and slightly lower solid cancer risk [0.97 (0.96-0.98)] but results varied by specific cancers and AD severity. CONCLUSIONS: Epidemiological evidence does not support a strong overall malignancy risk in AD but lymphoma risk may be increased with severe AD.
引用
- Wan J, Shin DB, Syed MN, et al. Malignancy risk in patients with atopic dermatitis: a population-based cohort study. Br J Dermatol. 2023. PMID: 37418646. doi:10.1093/bjd/ljad072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。